Review of frontline treatments for Philadelphia chromosome-positive ALL in adult patients

With the advent of potent BCR::ABL1 TKIs, Philadelphia chromosome-positive ALL has become a relatively favorable-risk ALL. A review of modern frontline treatments for Ph-positive ALL in adult patients showed promising results with chemotherapy-free regimens of blinatumomab plus TKIs, questioning the role of allogeneic stem-cell transplantation in first remission. Patients with Ph-positive ALL who achieve early and deep molecular responses have excellent long-term outcomes.